326 related articles for article (PubMed ID: 33349602)
21. Comparison of diagnostic criteria for polycythaemia vera.
Turkington RC; Arnold EC; Percy MJ; Ranaghan LA; Cuthbert RJ; McMullin MF
Hematology; 2007 Apr; 12(2):123-30. PubMed ID: 17454193
[TBL] [Abstract][Full Text] [Related]
22. A refined diagnostic algorithm for polycythemia vera that incorporates mutation screening for JAK2(V617F).
Tefferi A
Curr Hematol Malig Rep; 2006 Jun; 1(2):81-6. PubMed ID: 20425336
[TBL] [Abstract][Full Text] [Related]
23. Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis.
Williams DM; Kim AH; Rogers O; Spivak JL; Moliterno AR
Exp Hematol; 2007 Nov; 35(11):1641-6. PubMed ID: 17920755
[TBL] [Abstract][Full Text] [Related]
24. JAK2 V617F mutation testing in polycythemia vera: use and impact in an academic practice.
Means RT
Am J Med Sci; 2008 Oct; 336(4):327-9. PubMed ID: 18854675
[TBL] [Abstract][Full Text] [Related]
25. JAK2 unmutated erythrocytosis: 2023 Update on diagnosis and management.
Gangat N; Szuber N; Tefferi A
Am J Hematol; 2023 Jun; 98(6):965-981. PubMed ID: 36966432
[TBL] [Abstract][Full Text] [Related]
26. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as new possible minor criteria for diagnosis of polycythemia vera.
Kim MJ; Kwon SS; Ji YS; Lee MY; Kim KH; Lee N; Park SK; Won JH; Yoon SY
Int J Lab Hematol; 2023 Dec; 45(6):853-859. PubMed ID: 37501518
[TBL] [Abstract][Full Text] [Related]
27. JAK2 V617F mutation is rare in idiopathic erythrocytosis: a difference from polycythemia vera.
Yoshinaga K; Mori N; Wang YH; Tomita K; Shiseki M; Motoji T
Int J Hematol; 2008 Jul; 88(1):82-87. PubMed ID: 18528646
[TBL] [Abstract][Full Text] [Related]
28. The complete evaluation of erythrocytosis: congenital and acquired.
Patnaik MM; Tefferi A
Leukemia; 2009 May; 23(5):834-44. PubMed ID: 19295544
[TBL] [Abstract][Full Text] [Related]
29. Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation.
Laubach JP; Fu P; Jiang X; Salter KH; Potti A; Arcasoy MO
Exp Hematol; 2009 Dec; 37(12):1411-22. PubMed ID: 19815050
[TBL] [Abstract][Full Text] [Related]
30. A new polycythaemia vera-associated SOCS3 SH2 mutant (SOCS3F136L) cannot regulate erythropoietin responses.
Suessmuth Y; Elliott J; Percy MJ; Inami M; Attal H; Harrison CN; Inokuchi K; McMullin MF; Johnston JA
Br J Haematol; 2009 Nov; 147(4):450-8. PubMed ID: 19735488
[TBL] [Abstract][Full Text] [Related]
31. [How I manage polycythemia].
Lombardo G; Hafraoui K; Beguin Y; Vertenoeil G
Rev Med Liege; 2024 Feb; 79(2):110-115. PubMed ID: 38356428
[TBL] [Abstract][Full Text] [Related]
32. How to manage polycythemia vera.
Passamonti F
Leukemia; 2012 May; 26(5):870-4. PubMed ID: 22157736
[TBL] [Abstract][Full Text] [Related]
33. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
34. Polycythemia vera is not initiated by JAK2V617F mutation.
Nussenzveig RH; Swierczek SI; Jelinek J; Gaikwad A; Liu E; Verstovsek S; Prchal JF; Prchal JT
Exp Hematol; 2007 Jan; 35(1):32-8. PubMed ID: 17198871
[TBL] [Abstract][Full Text] [Related]
35. Beyond Hemoglobin: When and How to Work Up Possible Polycythemia Vera.
Shaw G; Berg R
Clin Med Res; 2020 Mar; 18(1):11-20. PubMed ID: 31582417
[TBL] [Abstract][Full Text] [Related]
36. In vitro culture growth of erythroid progenitors and serum erythropoietin assay in the differential diagnosis of polycythaemia.
Shih LY; Lee CT; See LC; Ou YC; Dunn P; Wang PN; Kuo MC; Wu JH
Eur J Clin Invest; 1998 Jul; 28(7):569-76. PubMed ID: 9726038
[TBL] [Abstract][Full Text] [Related]
37. Polycythaemia Vera among Sudanese Patients with Special Emphasis on JAK2 Mutations.
Ibrahim IK; Hassan R; Ali EW; Omer A
Asian Pac J Cancer Prev; 2019 Jan; 20(1):41-44. PubMed ID: 30677867
[TBL] [Abstract][Full Text] [Related]
38. Polycythemia vera: the current status of preclinical models and therapeutic targets.
Bartalucci N; Guglielmelli P; Vannucchi AM
Expert Opin Ther Targets; 2020 Jul; 24(7):615-628. PubMed ID: 32366208
[TBL] [Abstract][Full Text] [Related]
39. Characterization of murine JAK2V617F-positive myeloproliferative disease.
Bumm TG; Elsea C; Corbin AS; Loriaux M; Sherbenou D; Wood L; Deininger J; Silver RT; Druker BJ; Deininger MW
Cancer Res; 2006 Dec; 66(23):11156-65. PubMed ID: 17145859
[TBL] [Abstract][Full Text] [Related]
40. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; FoĆ R; Larocca LM
J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]